Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Hofseth BioCare. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Hofseth BioCare's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hofseth BioCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Hofseth BioCare's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Hofseth BioCare's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Hofseth BioCare's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Hofseth BioCare is high growth as no earnings estimate data is available.
Unable to determine if Hofseth BioCare is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Hofseth BioCare's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Roger Hofseth has been the Chief Executive Officer of Hofseth BioCare ASA since August 14, 2017. He is Director at Aqua Bio Technology ASA since January 9, 2019. Mr. Hofseth serves as the Chief Executive Officer of Hofseth International. Mr. Hofseth has 20 years of experience in the fishery and food industry. This experience includes the founding of several companies and holding the position as member of the board and/or management position in several companies within the fishery, fish farming and ecological food industry. He served as the Chairman of Hofseth BioCare ASA since January 4, 2016 and served as its Director since 2009 to September 2017. Mr. Hofseth serves as the Chairman for Norsk Fisketerminal, Roger Hofseth and Tyco Invest. He serves as a member of board of Directors at Syvde Eiendom AS, Forex Holding, Hofseth, Hofseth International and Seafood Farmers of Norway. Mr. Hofseth served as Director of Vanylven Vekst HF. He served as a Member of the Board of Directors of Hofseth Bio Care from June 2010 to October 2011.
Roger's compensation has been consistent with company performance over the past year, both up more than 20%.
Roger's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Hofseth BioCare management team is about average.
Chief Financial Officer
Chief Operating Officer
Chief Scientific Officer
Lab Manager & Director
Chief Executive Officer
Managing Partner of Hofseth North America
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Hofseth BioCare board of directors is about average.
Board of Directors
Chairman of the Board of Directors
Lab Manager & Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Hofseth BioCare individual insiders in the past 3 months.
Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company was founded in 2000 and is headquartered in Ålesund, Norway.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.